Confirming media reports, Baxter International announced it has agreed to sell its BioPharma Solutions (BPS) business to a private equity consortium of Warburg Pincus and Advent International for $4.25 billion in cash.
A private equity consortium of Warburg Pincus and Advent International is said to be in advanced talks to acquire medical device maker Baxter International’s biopharma solutions business. The deal could be worth $4 billion or more, news agencies and the newspaper Wall Street Journal reported.
Under the name Envalior, German specialty chemicals producer Lanxess and private equity investor Advent International launched their new 40:60 joint venture for high performance engineering plastics at the beginning of the second quarter, after the deal cleared all regulatory hurdles earlier.
2021 was historic for chemical M&As, it was a record-breaking year in terms of total value of deals. Therefore, it was expected that 2022 would only build upon this. However, the combination of high interest rates, supply chain bottlenecks and geopolitical instability saw both the number and value of deals take a significant hit throughout 2022.
With merger clearance granted by India this week, nothing now stands in the way of plans by German chemical producer Lanxess and private equity investor Advent International to create a 40:60 joint venture for high performance engineering plastics with annual sales of around €300 million.
The planned 60:40 specialty materials joint venture of German chemical producer and private equity group Advent International, announced at the end of May, is gradually taking on visible contours.
